Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2002;105:2423-2428
Published online before print April 29, 2002, doi: 10.1161/01.CIR.0000016047.19488.91
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
105/20/2423    most recent
01.CIR.0000016047.19488.91v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mueller, C.
Right arrow Articles by Nickenig, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mueller, C.
Right arrow Articles by Nickenig, G.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Related Collections
Right arrow Mechanism of atherosclerosis/growth factors
Right arrow Pathophysiology
Right arrow Cell signalling/signal transduction
Right arrow Gene expression
Right arrow Smooth muscle proliferation and differentiation

(Circulation. 2002;105:2423.)
© 2002 American Heart Association, Inc.


Basic Science Reports

Identification of a Novel Redox-Sensitive Gene, Id3, Which Mediates Angiotensin II–Induced Cell Growth

Cornelius Mueller, MD*; Stephanie Baudler, PhD*; Hilke Welzel, MD; Michael Böhm, MD; Georg Nickenig, MD

From the Klinik und Poliklinik Innere Medizin III, Universität des Saarlandes, Homburg, Germany.

Correspondence to Dr Georg Nickenig, Klinik und Poliklinik Innere Medizin III, Universität des Saarlandes, 66424 Homburg, Germany. E-mail nickenig{at}med-in.uni-sb.de


*    Abstract
up arrowTop
*Abstract
down arrowIntroduction
down arrowMethods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Background Reactive oxygen species, such as superoxide (O2-), are involved in the abnormal growth of various cell types. Angiotensin II (Ang II) is one of the most potent inducers of oxidative stress in the vasculature. The molecular events involved in Ang II–induced proliferation of vascular smooth muscle cells (VSMCs) are only partially understood.

Methods and Results Ang II as well as xanthine/xanthine oxidase (X/XO) led to enhanced DNA synthesis and proliferation of VSMCs. The effect of Ang II was abolished by diphenylene iodonium. Consequently, VSMCs were incubated with X/XO, and modulation of gene expression was monitored by differential display, leading to the identification of a novel redox-sensitive gene, the dominant-negative helix-loop-helix protein Id3, which was upregulated within 30 minutes by X/XO and Ang II. Superoxide dismutase but not catalase inhibited this effect. Overexpression of antisense Id3 via transfection in VSMCs completely abolished Ang II– and X/XO-induced cell proliferation. Ang II, X/XO, and overexpression of sense Id3 downregulated protein expression of p21WAF1/Cip1, p27Kip1, and p53. Overexpression of antisense Id3 abrogated the effect of Ang II on the expression of p21WAF1/Cip1, p27Kip1, and p53. Ang II and overexpression of sense Id3 caused hyperphosphorylation of the retinoblastoma protein. Ang II–induced phosphorylation of the retinoblastoma protein was decreased by overexpression of antisense Id3.

Conclusions Ang II induces proliferation of VSMCs via production of superoxide, which enhances the expression of Id3. Id3 governs the downstream mitogenic processing via depression of p21WAF1/Cip1, p27Kip1, and p53. These findings reveal a novel redox-sensitive pathway involved in growth control.


Key Words: oxygen • muscle, smooth • proteins • cells • angiotensin


*    Introduction
up arrowTop
up arrowAbstract
*Introduction
down arrowMethods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Proliferation of vascular smooth muscle cells (VSMCs) is a key event of atherogenesis and coronary restenosis.1,2 Growth of VSMCs is induced by various agonists such as growth factors (eg, epidermal growth factor, platelet-derived growth factor, insulin-like growth factor), cytokines, and hormones.14 Angiotensin II (Ang II) causes cell growth via activation of AT1 receptors.3,5 It shares with growth factors numerous mitogenic signaling pathways, including, eg, tyrosine phosphorylation, mitogen-activated protein (MAP) kinase activation, stimulation of the Janus kinase/signal transducers and activators of transcription system, and induction of proto-oncogenes.3,5 Whether Ang II exerts predominantly hypertrophic or also hyperplastic effects on VSMCs, however, is the subject of ongoing controversy.511 In this regard, the influence of Ang II on factors involved in cell cycle progression have not been completely understood.

Reactive oxygen species (ROS) are thought to mediate the mitogenic effects of Ang II via activation of, eg, MAP kinases.6 ROS, such as superoxide (O2-), are involved in a multiplicity of pathological settings, such as inflammation, cancer development, and vascular lesions.1216 ROS exert direct cell damage and mitogenicity, serve as intracellular second messengers, and scavenge vasoprotective nitric oxide.1720 The induction of cell growth in tumor cells and VSMCs by ROS is of fundamental relevance. O2- induces a wide array of second messengers typical of mitogens.1720 Proliferation, growth arrest, and apoptosis are key steps in various states of atherogenesis. Therefore, it is crucial to dissect the molecular events that govern ROS-induced regulation of proliferation.

Thus, we explored the effects of Ang II and X/XO on VSMC growth, investigated superoxide-elicited modulations of gene expression in VSMCs with the differential display method, and characterized the role of a newly identified gene in Ang II– and superoxide-caused cell proliferation.


*    Methods
up arrowTop
up arrowAbstract
up arrowIntroduction
*Methods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Cell Culture
VSMCs were isolated from rat thoracic aorta (male Sprague-Dawley rats, 6 to 10 weeks old, Charles River Wega GmbH, Sulzfeld, Germany) by enzymatic dispersion and cultured over several passages. Cells were grown in a 5% CO2 atmosphere at 37°C in DMEM supplemented with 100 U/mL penicillin, 100 µg/mL streptomycin, 1% nonessential amino acids (100x), and 10% FCS. Experiments were performed with cells from passages 5 to 15. For each experiment, cells were serum deprived 24 hours before the indicated treatment.

Assessment of Cell Proliferation
The rate of cell proliferation was determined with a cell proliferation ELISA (Roche Molecular Biochemicals) via incorporation of bromodeoxyuridine (BrdU) into newly synthesized DNA according to the manufacturer’s protocol. Briefly, VSMCs were plated on microtiter plates at a density of 104 cells per well. After 12 hours, cells were serum starved for 24 hours and treated with ROS for 24 hours. BrdU was added at a final concentration of 10 µmol/L, and cells were reincubated for an additional 12 hours at 37°C. Cells were fixed with fixation solution for 30 minutes at room temperature and incubated with 100 µL anti-BrdU peroxidase-labeled antibody for 90 minutes. After 3 washing steps with the washing solution provided, the substrate solution for the colorimetric quantification was added at a final concentration of 100 µL/mL and left at room temperature for 5 to 30 minutes until color development was sufficient for photometric detection.

For cell counting, VSMCs were serum-starved for 24 hours and treated as indicated. Cells were removed from the tissue culture dish by addition of trypsin, pelleted, resuspended in 1 mL of DMEM, and counted in a Neubauer chamber.

Isolation of RNA and Differential Display
Total RNA from ROS-treated and control cells was isolated by use of PEQGold RNAPure (PeqLab) according to the manufacturer’s protocol. To eliminate false-positive results generated from genomic DNA, the RNA was treated with 10 U RNase-free DNase I (Roche Molecular Biochemicals) for 30 minutes at 37°C and extracted with phenol/chloroform. Differential display of mRNA was carried out with the RNAimage mRNA differential display system (GenHunter Corp). Purified total RNA (2 µg) was reverse transcribed by use of 1 of the 3 provided H-T11-M primers (M = A, T, or G), and cDNA representing 200 ng of RNA was submitted to differential display polymerase chain reaction (PCR) by use of the respective H-T11-M primer and 1 of 8 arbitrary primers provided, 1 U of AmpliTaq DNA polymerase (Perkin-Elmer Corp), and 2 µCi [{alpha}-33P]dATP (ICN Biomedicals) per reaction. PCR was carried out with 40 cycles of 94°C for 30 seconds, 42°C for 2 minutes, and 72°C for 30 seconds, followed by a final extension step at 72°C for 5 minutes. PCR products were resolved on a 6% denaturing polyacrylamide gel in 1x Tris-borate-EDTA buffer followed by autoradiography. Reproducibly differentially expressed bands were cut out of the gel, and the cDNA was eluted by boiling for 15 minutes. The gel debris was pelleted by centrifugation, and the supernatant was transferred to a fresh microcentrifuge tube. The DNA was then precipitated by addition of 100% ethanol, incubation on dry ice for 30 minutes, and centrifugation at 4°C in an Eppendorf microcentrifuge. The pellet was washed with 85% vol/vol ethanol, dried, and resuspended in deionized distilled H2O. Reamplification of the purified cDNA was performed with the same primer set and PCR conditions as used for the differential display PCR. Reamplified cDNAs were either directly sequenced with the respective arbitrary primer or after cloning into the pCR2.2-vector (Invitrogen BV) via the thymidine-adenosine (TA) cloning method.

Northern Blot and Generation of Radiolabeled Probes
Total RNA (15 µg) was electrophoresed on a 1.2% agarose/0.67% formaldehyde gel. After electrophoresis, RNA was transferred onto Hybond N nylon membrane (Amersham Pharmacia Biotech). PCR fragments of 897 bp (Id3) and 1456 bp (GKLF) were radiolabeled with [{alpha}-32P]dCTP (ICN Biomedicals) by use of the Prime-It II random-primer labeling kit (Stratagene). Membranes were prehybridized in a solution containing 50% formamide, 6x SSC, 0.5% SDS, 5x Denhardt’s solution, and 100 µg/mL salmon testes DNA (Sigma-Aldrich GmbH) for >=30 minutes at 42°C. Hybridization was carried out in hybridization solution containing 50% formamide, 6x SSC, 0.5% SDS, 100 µg/mL salmon testes DNA, and the denatured radiolabeled probe in an overnight incubation at 42°C. Membranes were washed twice with 2x SSC and 2 to 4 times with 2x SSC/0.1% SDS at 50°C to 65°C, sealed in a plastic bag, and submitted to autoradiography.

Semiquantitative Reverse Transcription–PCR
Total RNA (2 µg) from ROS-treated and control cells were reverse transcribed by use of 100 pmol p(dN6) oligonucleotide primer (Roche Molecular Biochemicals) and 200 U of Moloney murine leukemia virus reverse transcriptase (Gibco BRL Life Technologies) in the supplied buffer for reverse transcription and 10 U RNasin (Promega). For PCR, 1 µL of each reaction was used with 50 pmol each of the respective primers for amplification of Id3 (sense, 5'-CGACATGAACCACTGCTACTC-3'; antisense, 5'-GGTCAGTGGCAAAAACTCCTC-3') in Red Taq PCR buffer, dNTP mix, and 1.25 U of Red Taq DNA polymerase (Sigma-Aldrich GmbH). PCR conditions were one 5-minute cycle of 95°C, followed by 25 cycles (GAPDH, 23 cycles) of 94°C for 30 seconds, 57°C (Id3) or 60°C (GAPDH) for 45 seconds, 72°C for 45 seconds, and a final extension for 10 minutes at 72°C. Twenty to 40 µL of each PCR reaction was analyzed on a 1% agarose Tris-acetate-EDTA gel and visualized by ethidium bromide staining, and optical densities of the cDNA bands were quantified. The same cDNA samples were used for the amplification of a 452-nt fragment of GAPDH (sense, 5'-ACCACAGTCCATGCCATCAC-3'; antisense, 5'-TCCACCA-CCCTGTTGCTGTA-3') to confirm that equal amounts of RNA were reverse transcribed.

Western Blotting
ROS-treated and control cells were washed twice with ice-cold PBS, scraped in 1 mL of ice-cold lysis buffer (100 mmol/L Tris, pH 6.8, 4% SDS, 20% glycerol, 0.1 mmol/L PMSF, 1 µg/mL leupeptin, 1 µg/mL aprotinin), heated to 95°C for 5 minutes, and stored at -20°C until use. Aliquots (40 µg) of the cell lysate were electrophoresed through a 0.1% SDS/10% polyacrylamide gel. Proteins were blotted to nitrocellulose membranes in a semidry blotting chamber (Pharmacia Biotech). Blot membranes were stained with Ponceau red to verify appropriate protein transfer and equal loading for each lane. Immunoblotting was performed overnight at 4°C. Antibody dilutions were p53 (Pab 240 mouse monoclonal IgG, sc-99, Santa Cruz Biotechnology Inc) 1:300, p27 (F-8 mouse monoclonal IgG, sc-1641, Santa Cruz) 1:300, p21 (mouse mixed monoclonal IgG, No. 05-345, Upstate Biotechnology, Biomol Hamburg) 1:600, Rb (M-153 rabbit polyclonal, sc-7905, Santa Cruz) 1:100, and Id3 (C-20 rabbit polyclonal, sc-490, Santa Cruz) 1:100. Immunodetection was done with the appropriate secondary antibody for 1 hour at room temperature (1:20 000 dilution, Sigma Chemical) and the enhanced chemiluminescence kit (Amersham). Autoradiography was performed at room temperature.

Plasmid Construction and Electroporation of VSMCs
Full-length cDNAs of Id3 were generated by PCR amplification of reverse-transcribed RNA derived from VSMCs (see above). Primers for Id3 were sense, 5'-CTCCAACCTCCAACATGAAGG-3'; antisense, 5'-GTTCAAAAATGGTTTATTATGCAAAATGTT-3'. PCR products were checked on a 1% Tris-acetate-EDTA agarose gel and cloned into the pCR2.2 vector (Invitrogen BV) via TA cloning. The orientation and validity of the insert were determined by automated sequencing, and Id3 sense and antisense constructs for electroporation were generated by cloning 912-bp BamHI/EcoRV fragments (NM_013058) into the pcDNA3 vector. For electroporation, VSMCs grown at a confluent monolayer were removed from the culture dish by addition of trypsin and pelleted. The pellet was resuspended in 200 µL of Optimem I (Gibco BRL Life Technologies), and cells were counted. For each sample, 106 cells were incubated with 20 µg of the respective DNA in precooled cuvettes (Promega) for 30 minutes on ice. After the cuvette had been warmed to 37°C for 30 seconds in a water bath, electroporation was performed for 16 ms at 0.3 kV and 500 µF. After an additional incubation for 30 minutes at room temperature, cells were plated on the appropriate culture dishes or microtiter plates.

Apoptosis
The rate of apoptosis in Id3-transfected cells was assessed with the cell death detection ELISAPLUS System (Molecular Biochemicals). The test principle is based on the determination of the amount of nucleosomes generated during the apoptotic fragmentation of cellular DNA. Cells were scraped and collected by centrifugation for 5 minutes at 1500 rpm (Heraeus Megafuge 1.0) and washed in 1 mL DMEM. The pellet was then resuspended in 0.5 mL incubation buffer and left at 4°C for 30 minutes; after centrifugation for 10 minutes at 15 000 rpm and 4°C in a microcentrifuge, 200 µL of supernatant was diluted in 1.8 mL of incubation buffer. From each sample, 100 µL was incubated in anti-histone–coated microtiter-plate wells for 90 minutes, the wells were washed 3 times with incubation buffer, and 100 µL of anti–DNA-peroxidase–linked antibody was added, followed by further incubation for 90 minutes. After 3 washing steps with incubation buffer, 100 µL of ABTS substrate solution for the peroxidase was added, and after 10 to 20 minutes, the rate of apoptosis was determined by photometric measurement at 492 nm.


*    Results
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMethods
*Results
down arrowDiscussion
down arrowReferences
 
Cultured rat VSMCs were incubated with 1 µmol/L Ang II with or without 30 minutes of pretreatment with 100 µmol/L diphenylene iodonium (DPI) and with xanthine 100 µmol/L, xanthine oxidase 1.6x10-3 U/mL (X/XO) to induce production of O2-. After a 24-hour incubation, DNA synthesis and cell proliferation were assessed. Figure 1, A and B, shows that Ang II caused a significant increase in DNA synthesis and cell proliferation that was inhibited by pretreatment with DPI. Consequently, X/XO also caused a significant increase in DNA synthesis and cell proliferation. Both Ang II–induced (maximal at 1 µmol/L) and X/XO-induced (maximal at 100 µmol/L) mitogenicities were concentration dependent (data not shown). These data suggest that Ang II exerts potent mitogenic effects via release of ROS.



View larger version (19K):
[in this window]
[in a new window]
 
Figure 1. Mitogenicity of Ang II and superoxide in VSMCs. VSMCs were incubated with 1 µmol/L Ang II (angII) in the presence or absence of 20 µmol/L DPI and with X/XO. After a 24-hour incubation, DNA synthesis (A) was assessed by BrdU labeling and cell proliferation (B) was quantified by cell counting. n=3 to 5. *P<0.05 angII or X/XO vs control; **P<0.05 angII vs angII+DPI.

To clarify the underlying molecular mechanisms, VSMCs were incubated with 100 µmol/L X/XO for 0, 0.5, 2, and 4 hours before total RNA was extracted and digested with DNase I. Gene expression modulation was monitored by the differential display technique with various supplied primer combinations. Several cDNA amplification products were differentially regulated by X/XO. Isolation, purification, subcloning, and automated sequencing led to the identification of the dominant-negative helix-loop-helix protein Id3. The full-length rat Id3 cDNA was cloned by PCR and subcloned in pcDNA3, and nucleotide composition was checked by automated sequencing. For confirmation of the differential display results, cells were incubated for the indicated time points with either 1 µmol/L Ang II or 100 µmol/L X/XO, RNA was isolated, and semiquantitative PCR and Northern blotting were performed. Id3 is profoundly upregulated within 0.5 hours by both Ang II and X/XO (Figure 2, A and B). This effect is concentration dependent, with a maximum at 1 µmol/L Ang II and 100 µmol/L X/XO (data not shown). Id3 protein expression is comparably upregulated by Ang II and X/XO, as assessed by Western blots (Figure 2, C and D). In addition, it was shown that a 30-minute pretreatment of VSMCs with DPI inhibits the Ang II–caused upregulation of Id3. In addition, cells were incubated with 1 µmol/L Ang II and 100 µmol/L X/XO in the presence of 200 U/L catalase or superoxide dismutase. Thirty minutes later, Id3 mRNA expression was assessed by Northern blots. Figure 2E reveals that superoxide dismutase rather than catalase inhibits the effects of Ang II and X/XO on Id3 expression. These findings demonstrate the identification of a novel redox-sensitive gene, Id3, which is induced in VSMCs on stimulation with Ang II via production of superoxide radicals.



View larger version (58K):
[in this window]
[in a new window]
 
Figure 2. Ang II and superoxide upregulate Id3 expression. Cells were incubated for the indicated times with either 1 µmol/L Ang II or 100 µmol/L X/XO, RNA was isolated, and semiquantitative PCR was performed at the exponential phase. Id3 mRNA expression was induced within 0.5 hour by both Ang II (A) and X/XO (B). Id3 protein expression was assessed by Western blots after stimulation of VSMCs with 1 µmol/L Ang II, 20 µmol/L DPI, or both (C) or with 100 µmol/L X/XO (D) for the indicated times. Autoradiographs representative of 3 to 5 experiments are depicted. Cells were also incubated with 1 µmol/L Ang II or 100 µmol/L X/XO in the presence of 200 U/L catalase (CAT) or superoxide dismutase (SOD). After a 30-minute incubation, RNA was isolated and Northern blots were performed to quantify Id3 mRNA expression. Densitometric analysis (E). n=3. *P<0.05.

Ang II and O2- both cause proliferation of VSMCs. Id3 is a dominant-negative helix-loop-helix protein expressed in various cell types. To characterize the role of Id3 in Ang II–induced proliferation of VSMC growth, full-length sense and antisense Id3 cDNAs inserted into the expression vector pcDNA3 were transfected into VSMCs via electroporation. By this technology, transfection efficiencies of {approx}30% were ensured. Control experiments showed reduced and enhanced expression of Id3 after the respective transfection (Figure 3A). Transfected cells were stimulated with vehicle, 1 µmol/L Ang II with or without 30 minutes of pretreatment with 20 µmol/L DPI, and 100 µmol/L X/XO. Figure 3B demonstrates that Ang II–induced DNA synthesis was abrogated by overexpression of antisense Id3. Overexpression of sense Id3 slightly increased the basal DNA synthesis. Consistently, superoxide-induced VSMC mitogenicity was diminished by antisense Id3 overexpression, as depicted in Figure 3C. Control experiments show that other genes, such as 18S rRNA or the AT1 receptor mRNA, were not influenced by either sense or antisense Id3, suggesting a specific effect of Id3 on the cell growth machinery (data not shown). Therefore, Ang II–driven superoxide release may cause VSMC proliferation via induction of Id3. To test whether the Id3 antisense effects were mediated via an increased rate of cell death, after transfection with the insertless vector, antisense Id3, and sense Id3, apoptosis was quantified in VSMCs. Figure 3D demonstrates that sense Id3 but not antisense Id3 induces increased apoptosis events in VSMCs.



View larger version (21K):
[in this window]
[in a new window]
 
Figure 3. Id3 essentially mediates mitogenicity of Ang II and superoxide. Full-length sense and antisense Id3 cDNAs inserted into pcDNA3 were transfected via electroporation in VSMCs. Transfection efficiencies were assessed by Western blot in cells transfected with the insertless pcDNA3, sense Id3, and antisense Id3 cDNAs (A). Transfected cells were stimulated with either vehicle (control), 1 µmol/L Ang II (angII) in the presence or absence of 20 µmol/L DPI (B), or 100 µmol/L X/XO (C) for 24 hours before DNA synthesis was assessed by BrdU labeling. n=3 to 6. B, *P<0.05 control vs angII. C, *P<0.05 control vs X/XO of pcDNA3; *P<0.05 control vs X/XO. D, Apoptosis in VSMCs 48 hours after transfection with the expression vector pcDNA3, a pcDNA3-sense Id3 construct, or a pcDNA3-antisense Id3 construct. n=3. *P<0.05 pcDNA3 vs Id3 sense.

Cyclin-dependent kinase (Cdk) inhibitors (CKIs) and the tumor suppressor protein p53 are essential regulators of growth. To determine whether Ang II– and superoxide-induced VSMC proliferation is associated with the modulation of CKIs, VSMCs were stimulated with either vehicle, 1 µmol/L Ang II, or 100 µmol/L X/XO before cellular proteins were isolated and Western blots were performed to quantify protein expression of p21WAF1/Cip1, p27Kip1, and p53. Figure 4, A and B, shows that Ang II and X/XO depress the expression of p21WAF1/Cip1, p27Kip1, and p53, suggesting that the decreased expression of p53 and Cdks is a prerequisite to the observed VSMC proliferation.



View larger version (44K):
[in this window]
[in a new window]
 
Figure 4. Ang II and superoxide decrease protein expression of p21WAF1/Cip1, p27 and p53. VSMCs were stimulated with either vehicle, 1 µmol/L Ang II, or 100 µmol/L X/XO for the indicated times, proteins were isolated, and Western blots were performed to detect protein expression of p21WAF1/Cip1, p27, and p53. A, Effect of Ang II; B, effect of X/XO. Autoradiographs are representative of 3 to 5 experiments.

Next, the role of Id3 was defined in the Ang II– and superoxide-induced regulation of Cdks and p53. Cells were transfected with sense and antisense Id3, followed by stimulation with 1 µmol/L Ang II. Figure 5 shows that overexpression of antisense Id3 inhibited Ang II–caused downregulation of p21WAF1/Cip1, p27Kip1, and p53, indicating that induction of Id3 by Ang II or superoxide leads causally to the depression of p53 and the Cdks p21WAF1/Cip1 and p27Kip1.



View larger version (57K):
[in this window]
[in a new window]
 
Figure 5. Ang II–induced depression of p21WAF1/Cip1, p27, and p53 is mediated through Id3. VSMCs were transfected with sense and antisense Id3, followed by stimulation with vehicle or 1 µmol/L Ang II for 24 hours. Cellular proteins were isolated, and Western blots were performed to detect protein expression of p21WAF1/Cip1, p27, and p53. Autoradiographs are representative of 3 separate experiments.

The retinoblastoma gene product (Rb) is hyperphosphorylated in VSMCs stimulated with 1 µmol/L Ang II (Figure 6). Ang II–induced Rb hyperphosphorylation was diminished by overexpression of antisense Id3, suggesting that Ang II induces Rb through induction of Id3.



View larger version (38K):
[in this window]
[in a new window]
 
Figure 6. Rb is hyperphosphorylated by Ang II via Id3 in VSMCs. Cells were stimulated with vehicle or 1 µmol/L Ang II (angII) for 24 hours. Before stimulation, VSMCs were transfected with pcDNA3 and sense and antisense Id3 (B). Rb was detected after isolation of VSMC proteins by Western blot. Autoradiographs are representative of 3 experiments.


*    Discussion
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMethods
up arrowResults
*Discussion
down arrowReferences
 
Cardiovascular complications of atherosclerosis, such as myocardial infarction and stroke, are the primary causes of death in the Western world.21,22 Atherosclerosis represents a vascular process characterized by, among other things, a pathogenic growth of VSMCs.1,2 Proliferation of VSMCs has been extensively investigated within the last few years, and the following events have been identified as essential. Agonists such as growth factors or hormones stimulate their receptors and activate a multiplicity of intracellular pathways, such as various protein kinases, MAP kinases, and proto-oncogenes, which ultimately accelerate the proliferation of VSMCs.3,5 Downstream of these early events, Cdks, CKIs, cofactors, and target genes and proteins are of great relevance for the cell-cycle progress that precedes enhanced cell growth.2325 CKIs such as p21WAF1/Cip1 and p27Kip1, the tumor suppressor protein p53, and Rb are engaged in the tight control of cell growth.25,26 It has been shown in various cell types that depression of CKIs and p53 expression and the hyperphosphorylation of Rb are sufficient to induce proliferation.25,26

Ang II mediates a wide array of biological effects, including the enhanced production of ROS and cell proliferation.3,5 Several interventional studies, above all the Heart Outcomes Prevention Evaluation (HOPE) Study, have clearly demonstrated that Ang II plays a decisive role in atherogenesis.27 There is a great body of evidence that these growth-stimulating features of Ang II are responsible for the impact of Ang II on the pathogenesis of atherosclerosis,13,20 yet it has not been clearly shown whether Ang II leads to hyperplasia rather than to hypertrophy of VSMCs.5,711 Moreover, the intracellular pathways governing these mitogenic processes are poorly defined. It is well established that Ang II causes early cellular events, such as stimulation of phospholipase C, protein kinase C, MAP kinases, and proto-oncogenes, which are typical for growth-promoting agonists.26,29 The subsequent cellular steps are less clear, especially with regard to cell cycle progression.

The data presented show that Ang II induces the production of superoxide, which mediates proliferation of VSMCs. This is in good agreement with previous reports demonstrating that free radicals are essential for the mitogenic effects of Ang II.28,30 It was recently reported that Ang II could not depress p27Kip1 but was capable of stimulating Cdk2 activity in VSMCs.8 In renal proximal tubular cells, Ang II induced the expression of p27Kip1.29 A different study was not able to show an effect of Ang II on Rb, Cdks, or p27Kip1,9 whereas another research group detected an increase of Cdk activity and Rb phosphorylation after Ang II stimulation.7 Neither the cellular or molecular events that could explain these conflicting results nor the detailed mechanisms involved in Ang II–evoked growth are known. Here, we report not only that Ang II induces redox-mediated cell proliferation but also that Ang II and superoxide profoundly depress growth-inhibiting factors, such as p53, p21WAF1/Cip1, and p27Kip1 and cause hyperphosphorylation of Rb, which allows binding of the growth-inhibiting factor E2F.

This is governed by the induction of Id3, as elucidated with the differential display gene-hunting method. Id3 antagonizes the function of DNA-binding basic helix-loop-helix transcription factors, such as E2A, leading to decreased cell differentiation and increased proliferation.31 In addition, Id3 has been implicated in the apoptosis of fibroblasts.32 The helix-loop-helix transcription factor E2A, which is scavenged by Id3, stimulates the transcription of p21WAF1/Cip1, suggesting that induction of Id3 could lead to decreased expression of p21WAF1/Cip1 accompanied by proliferation. This is consistent with our data, which demonstrate that induction of Id3 is a prerequisite to Ang II– and superoxide-evoked depression of p21WAF1/Cip1. Moreover, Id3 influences p27Kip1, p53, and Rb in a similar manner, suggesting that Id3 resides in a central position upstream of Cdks, CKIs, p53, and Rb, which ascribes to Id3 a crucial significance for growth control in VSMCs.

The results described have several implications. Ang II causes VSMC growth through superoxide production. This results in depression of the CKIs p21WAF1/Cip1 and p27Kip1, as well as the tumor suppressor gene product p53. Consequently, Rb is hyperphosphorylated. These events are specifically mediated through Id3. The data not only significantly advance our understanding of growth processes in general, but the gene-hunting approach also provided us with a newly described redox-sensitive gene that could be used for the forced induction of proliferation arrest of VSMCs. This ultimately could be implemented in novel treatment strategies for atherosclerosis and restenosis.


*    Acknowledgments
 
This work was supported by the Deutsche Forschungsgemeinschaft and by the Deutsche Herzstiftung.


*    Footnotes
 
*The first 2 authors contributed equally to this work. Back

Received July 26, 2001; revision received March 1, 2002; accepted March 1, 2002.


*    References
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMethods
up arrowResults
up arrowDiscussion
*References
 

  1. Badimon JJ, Fuster V, Chesebro JH, et al. Coronary atherosclerosis: a multifactorial disease. Circulation. 1993; 87: 113–116.
  2. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. N Engl J Med. 1993; 362: 801–809.
  3. Berk BC. Angiotensin II signal transduction in vascular smooth muscle: pathways activated by specific tyrosine kinases. J Am Soc Nephrol. 1999; 10: 62–68.[Abstract/Free Full Text]
  4. Pratt RE. Angiotensin II and the control of cardiovascular structures. J Am Soc Nephrol. 1999; 10: 120–128.
  5. Griendling KK, Ushio-Fukai M, Lassegue B, et al. Angiotensin II signaling in vascular smooth muscle. Hypertension. 1997; 29: 366–373.[Abstract/Free Full Text]
  6. Berk BC. Angiotensin II signal transduction in vascular smooth muscle: pathways activated by specific tyrosine kinases. J Am Soc Nephrol. 1999; 10 (suppl 11): S62–S68.
  7. Sadoshima J, Aoki H, Izumo S. Angiotensin II and serum differentially regulate expression of cyclins, activity of cyclin-dependent kinases, and phosphorylation of retinoblastoma gene product in neonatal cardiac myocytes. Circ Res. 1997; 80: 228–241.[Abstract/Free Full Text]
  8. Braun-Dullaeus RC, Mann MJ, Ziegler A, et al. A novel role for the cyclin-dependent kinase inhibitor p27(Kip1) in angiotensin II-stimulated vascular smooth muscle cell hypertrophy. J Clin Invest. 1999; 104: 815–823.[Medline] [Order article via Infotrieve]
  9. Rao GN. Differential regulation of p27 kip1 levels and CDK activities by hypertrophic and hyperplastic agents in vascular smooth muscle cells. Biochem Biophys Acta. 1999; 1448: 525–532.[Medline] [Order article via Infotrieve]
  10. Servant MG, Coulombe P, Turgeon B, et al. Differential regulation of p27 (Kip1) expression by mitogenic and hypertrophic factors: involvement of transcriptional and posttranscriptional mechanisms. J Cell Biol. 2000; 148: 543–556.[Abstract/Free Full Text]
  11. Yamakawa T, Tanaka S, Numaguchi K, et al. Involvement of Rho-kinase in angiotensin II–induced hypertrophy of rat vascular smooth muscle cells. Hypertension. 2000; 35: 313–318.[Abstract/Free Full Text]
  12. Grisham MB, Jourd’heuil D, Wink DA. Review article: chronic inflammation and reactive oxygen and nitrogen metabolism: implications in DNA damage and mutagenesis. Aliment Pharmacol Ther. 2000; 14 (suppl 1): 3–9.
  13. Marnett LJ. Oxyradicals and DNA damage. Carcinogenesis. 2000; 21: 361–370.[Abstract/Free Full Text]
  14. Mates JM, Perez-Gomez C, Nunez I. Antioxidant enzymes and human diseases. Clin Biochem. 1999; 32: 595–603.[CrossRef][Medline] [Order article via Infotrieve]
  15. Mates JM, Sanchez-Jimenez FM. Role of reactive oxygen species in apoptosis: implications for cancer therapy. Int J Biochem Cell Biol. 2000; 32: 157–170.[CrossRef][Medline] [Order article via Infotrieve]
  16. Patel RP, Moellering D, Murphy-Ullrich J, et al. Cell signaling by reactive nitrogen and oxygen species in atherosclerosis. Free Radic Biol Med. 2000; 28: 1780–1794.[CrossRef][Medline] [Order article via Infotrieve]
  17. Griendling KK, Sorescu D, Ushio-Fukai M. NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res. 2000; 86: 494–501.[Abstract/Free Full Text]
  18. Irani K. Oxidant signaling in vascular cell growth, death, and survival: a review of the roles of reactive oxygen species in smooth muscle and endothelial cell mitogenic and apoptotic signaling. Circ Res. 2000; 87: 179–183.[Abstract/Free Full Text]
  19. Zalba G J, Beaumont G, San Jose A, et al. Vascular oxidant stress: molecular mechanisms and pathophysiological implications. J Physiol Biochem. 2000; 56: 57–64.[Medline] [Order article via Infotrieve]
  20. Berk BC. Redox signals that regulate the vascular response to injury. Thromb Haemost. 1999; 82: 810–817.[Medline] [Order article via Infotrieve]
  21. WHO-MONICA Project. Myocardial infarction and coronary deaths in the World Health Organization Project: registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents. Circulation. 1994; 90: 583–612.[Abstract/Free Full Text]
  22. Gutzwiller F. Monitoring of cardiovascular disease and risk factor trends: experiences from the WHO/MONICA project. Ann Med. 1994; 26: 61–65.[Medline] [Order article via Infotrieve]
  23. Tanner FC, Boehm M, Akyurek LM, et al. Differential effects of the cyclin-dependent kinase inhibitors p27(Kip1), p21(Cip1), and p16(Ink4) on vascular smooth muscle cell proliferation. Circulation. 2000; 101: 2022–2025.[Abstract/Free Full Text]
  24. Weiss RH, Joo A, Randour C. p21(Waf1/Cip1) is an assembly factor required for platelet-derived growth factor-induced vascular smooth muscle cell proliferation. J Biol Chem. 2000; 275: 10285–10290.[Abstract/Free Full Text]
  25. Zettler ME, Pierce GN. Cell cycle proteins and atherosclerosis. Herz. 2000; 25: 100–107.[CrossRef][Medline] [Order article via Infotrieve]
  26. Rivard A, Andrés V. Vascular smooth muscle cell proliferation in pathogenesis of atherosclerotic cardiovascular diseases. Histol Histopathol. 2000; 15: 557–571.[Medline] [Order article via Infotrieve]
  27. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000; 342: 145–153.[Abstract/Free Full Text]
  28. Rao GN, Berk BC. Active oxygen species stimulate vascular smooth muscle cell growth and proto-oncogene expression. Circ Res. 1992; 70: 593–599.[Abstract/Free Full Text]
  29. Hannken TR, Schroeder G, Zahner RA, et al. Reactive oxygen species stimulate p44/42 mitogen-activated protein kinase and induce p27(Kip1): role in angiotensin II-mediated hypertrophy of proximal tubular cells. J Am Soc Nephrol. 2000; 11: 1387–1397.[Abstract/Free Full Text]
  30. Zafari AM, Ushio-Fukai M, Akers M, et al. Role of NADH/NADPH oxidase-derived H2O2 in angiotensin II–induced vascular hypertrophy. Hypertension. 1992; 32: 488–495.[Abstract/Free Full Text]
  31. Prabhu S, Ignatova A, Park ST, et al. Regulation of the expression of cyclin dependent kinase inhibitor p21 by E2A and Id proteins. Mol Cell Biol. 1997; 17: 5888–5896.[Abstract]
  32. Norton JD, Atherton GT. Coupling of cell growth control and apoptosis functions of Id proteins. Mol Cell Biol. 1998; 18: 2371–2381.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
H. Deliri and C. A. McNamara
Nox 4 Regulation of Vascular Smooth Muscle Cell Differentiation Marker Gene Expression
Arterioscler. Thromb. Vasc. Biol., January 1, 2007; 27(1): 12 - 14.
[Full Text] [PDF]


Home page
Cardiovasc ResHome page
R. E. Clempus and K. K. Griendling
Reactive oxygen species signaling in vascular smooth muscle cells
Cardiovasc Res, July 15, 2006; 71(2): 216 - 225.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
A. E. Vendrov, N. R. Madamanchi, Z. S. Hakim, M. Rojas, and M. S. Runge
Thrombin and NAD(P)H Oxidase-Mediated Regulation of CD44 and BMP4-Id Pathway in VSMC, Restenosis, and Atherosclerosis
Circ. Res., May 26, 2006; 98(10): 1254 - 1263.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
A. M. Taylor, R. Hanchett, R. Natarajan, C. C. Hedrick, S. Forrest, J. L. Nadler, and C. A. McNamara
The Effects of Leukocyte-Type 12/15-Lipoxygenase on Id3-Mediated Vascular Smooth Muscle Cell Growth
Arterioscler. Thromb. Vasc. Biol., October 1, 2005; 25(10): 2069 - 2074.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
P. B. Yu, H. Beppu, N. Kawai, E. Li, and K. D. Bloch
Bone Morphogenetic Protein (BMP) Type II Receptor Deletion Reveals BMP Ligand-specific Gain of Signaling in Pulmonary Artery Smooth Muscle Cells
J. Biol. Chem., July 1, 2005; 280(26): 24443 - 24450.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
T. Kanda, K. Hayashi, S. Wakino, K. Homma, K. Yoshioka, K. Hasegawa, N. Sugano, S. Tatematsu, I. Takamatsu, T. Mitsuhashi, et al.
Role of Rho-Kinase and p27 in Angiotensin II-Induced Vascular Injury
Hypertension, April 1, 2005; 45(4): 724 - 729.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
S. H.M. Ellmark, G. J. Dusting, M. Ng Tang Fui, N. Guzzo-Pernell, and G. R. Drummond
The contribution of Nox4 to NADPH oxidase activity in mouse vascular smooth muscle
Cardiovasc Res, February 1, 2005; 65(2): 495 - 504.
[Abstract] [Full Text] [PDF]


Home page
GENES CELLSHome page
Y. Aoki, S. Mori, K. Kitajima, O. Yokoyama, H. Kanamaru, K. Okada, and Y. Yokota
Id2 haploinsufficiency in mice leads to congenital hydronephrosis resembling that in humans
Genes Cells, December 1, 2004; 9(12): 1287 - 1296.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
S. Forrest and C. McNamara
Id Family of Transcription Factors and Vascular Lesion Formation
Arterioscler. Thromb. Vasc. Biol., November 1, 2004; 24(11): 2014 - 2020.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
S. T. Forrest, A. M. Taylor, I. J. Sarembock, D. Perlegas, and C. A. McNamara
Phosphorylation Regulates Id3 Function in Vascular Smooth Muscle Cells
Circ. Res., September 17, 2004; 95(6): 557 - 559.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
M. Dupuis, F. Soubrier, I. Brocheriou, S. Raoux, M. Haloui, L. Louedec, J.-B. Michel, and S. Nadaud
Profiling of Aortic Smooth Muscle Cell Gene Expression in Response to Chronic Inhibition of Nitric Oxide Synthase in Rats
Circulation, August 17, 2004; 110(7): 867 - 873.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. T. Forrest, K. G. Barringhaus, D. Perlegas, M.-L. Hammarskjold, and C. A. McNamara
Intron Retention Generates a Novel Id3 Isoform That Inhibits Vascular Lesion Formation
J. Biol. Chem., July 30, 2004; 279(31): 32897 - 32903.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
M. S. Kumar and G. K. Owens
Combinatorial Control of Smooth Muscle-Specific Gene Expression
Arterioscler. Thromb. Vasc. Biol., May 1, 2003; 23(5): 737 - 747.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart J SupplHome page
N. Werner and G. Nickenig
AT1 receptors in atherosclerosis: biological effects including growth, angiogenesis, and apoptosis
Eur. Heart J. Suppl., January 1, 2003; 5(suppl_A): A9 - A13.
[Abstract] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
105/20/2423    most recent
01.CIR.0000016047.19488.91v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mueller, C.
Right arrow Articles by Nickenig, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mueller, C.
Right arrow Articles by Nickenig, G.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Subs